Search - tctmd.com

Displaying 1 - 20 of 27

Sort: Relevancy | Date

Presentation TCT 2024

Transcatheter vs. Surgical Aortic Valve Replacement in Women: A Pooled Analysis of the RHEIA and PARTNER 3 Trials

Presenter: Didier Tchetche

October 29, 2024

Presentation TCT 2021

PARTNER 3: Two-Year Economic Outcomes From a Randomized Trial of TAVR vs. SAVR in Patients at Low Surgical Risk

Presenter: David Cohen

November 05, 2021

Presentation TCT 2020

Five-Year Follow-Up from the PARTNER 2 Aortic Valve-in-Valve Registries: Clinical Outcomes, Valve Function, and Durability

Presenter: Rebecca T. Hahn

October 17, 2020

Presentation TCT 2020

TAVR in Low Surgical Risk Patients - Evidence Updates From PARTNER 3

Presenter: Martin Leon

October 16, 2020

Presentation TCT 2019

PARTNER 2A: 5-Year Outcomes From a Randomized Trial of Transcatheter vs. Surgical Aortic Valve Replacement in Intermediate-Risk Patients With Severe Aortic Stenosis

Presenter: Vinod Thourani

September 28, 2019

Presentation TCT 2019

PARTNER 3 Low-Risk Computed Tomography Substudy: Subclinical Leaflet Thrombosis in Transcatheter and Surgical Bioprosthetic Valves

Presenter: Raj Makkar

September 27, 2019

Presentation TVT 2019

Comparing the Low-Risk Trials (PARTNER 3 and Medtronic Low-Risk)

Presenter: Martin Leon

June 13, 2019

Presentation TVT 2019

The PARTNER 3 Low-Risk Randomized Trial

Presenter: Susheel Kodali

June 13, 2019

Presentation TVT 2019

Incidence, Trends, Risk Factors, and Comparison With Surgery for Early Stroke After TAVR: Reports From PARTNER and the TVT Registry (in High- and Intermediate-Risk Patients)

Presenter: Samir Kapadia

June 13, 2019

Presentation TCT 2018

PARTNER VALVE-IN-VALVE: Late Follow-up After Treatment of Failing Surgical Aortic Bioprosthetic Valves With a Balloon-Expandable Transcatheter Heart Valve

Presenter: John G. Webb

September 23, 2018

Presentation The Structural Heart Disease Summit 2018

Strokes After Transfemoral TAVR vs SAVR: A Propensity-Matched Analysis From the PARTNER Trial

Presenter: Eberhard Grube, Tamim Nazif, Chetan P. Huded

June 21, 2018

Presentation TCT 2017

Hemodynamic Trends on Serial Echocardiograms after TAVR: Comprehensive 5-Year Analyses From PARTNER

Presenter: Pamela S. Douglas

November 01, 2017

Presentation TCT 2017

Important Clinical Lessons From the VIVID Registry and the PARTNER Experience

Presenter: John G. Webb

October 30, 2017

Presentation TCT 2017

The PARTNER 3 Low-risk Trial

Presenter: Michael J. Mack

October 30, 2017

Presentation TCT 2017

Viewpoint #1: PARTNER 2A and SURTAVI are Convincing TAVR is Preferred in ALL (Appropriate) Intermediate-Risk Patients

Presenter: Michael J. Reardon

October 30, 2017

Presentation TCT 2017

Case Presentation 6: BTK Intervention

Presenter: Sergey A. Abugov, Juan F. Granada, Zaza Kavteladze

October 29, 2017

Presentation TCT 2017

Editorial Comment

Presenter: Sergey A. Abugov, Juan F. Granada, Susheel K. Kodali

October 29, 2017

Presentation TCT 2017

Case Presentation 5: TAVR

Presenter: Sergey A. Abugov, Juan F. Granada, Alexey Protopopov

October 29, 2017

Presentation TCT 2017

Tricuspid Valve Interventions: Patient Selection, Devices, and Predictions

Presenter: Antonio Colombo, Samir R. Kapadia, Azeem Latib

October 29, 2017

Presentation TCT 2017

Mitral Valve Interventions: MitraClip, Annular Treatments, and Valves Where Will We Be in 5 Years? In 10 Years?

Presenter: Antonio Colombo, Azeem Latib, Jason H. Rogers

October 29, 2017

Advertisement

Transcatheter vs. Surgical Aortic Valve Replacement in Women: A Pooled Analysis of the RHEIA and PARTNER 3 Trials

PARTNER 3: Two-Year Economic Outcomes From a Randomized Trial of TAVR vs. SAVR in Patients at Low Surgical Risk

Five-Year Follow-Up from the PARTNER 2 Aortic Valve-in-Valve Registries: Clinical Outcomes, Valve Function, and Durability

TAVR in Low Surgical Risk Patients - Evidence Updates From PARTNER 3

PARTNER 2A: 5-Year Outcomes From a Randomized Trial of Transcatheter vs. Surgical Aortic Valve Replacement in Intermediate-Risk Patients With Severe Aortic Stenosis

PARTNER 3 Low-Risk Computed Tomography Substudy: Subclinical Leaflet Thrombosis in Transcatheter and Surgical Bioprosthetic Valves

Comparing the Low-Risk Trials (PARTNER 3 and Medtronic Low-Risk)

The PARTNER 3 Low-Risk Randomized Trial

Incidence, Trends, Risk Factors, and Comparison With Surgery for Early Stroke After TAVR: Reports From PARTNER and the TVT Registry (in High- and Intermediate-Risk Patients)

PARTNER VALVE-IN-VALVE: Late Follow-up After Treatment of Failing Surgical Aortic Bioprosthetic Valves With a Balloon-Expandable Transcatheter Heart Valve

Strokes After Transfemoral TAVR vs SAVR: A Propensity-Matched Analysis From the PARTNER Trial

Hemodynamic Trends on Serial Echocardiograms after TAVR: Comprehensive 5-Year Analyses From PARTNER

Important Clinical Lessons From the VIVID Registry and the PARTNER Experience

The PARTNER 3 Low-risk Trial

Viewpoint #1: PARTNER 2A and SURTAVI are Convincing TAVR is Preferred in ALL (Appropriate) Intermediate-Risk Patients

Case Presentation 6: BTK Intervention

Editorial Comment

Case Presentation 5: TAVR

Tricuspid Valve Interventions: Patient Selection, Devices, and Predictions

Mitral Valve Interventions: MitraClip, Annular Treatments, and Valves Where Will We Be in 5 Years? In 10 Years?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content